Callan Capital LLC Boosts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Callan Capital LLC lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,950 shares of the company’s stock after acquiring an additional 1,750 shares during the quarter. Callan Capital LLC’s holdings in Tarsus Pharmaceuticals were worth $343,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Deerfield Management Company L.P. Series C acquired a new position in shares of Tarsus Pharmaceuticals during the third quarter worth $13,399,000. Artisan Partners Limited Partnership acquired a new position in shares of Tarsus Pharmaceuticals during the third quarter worth $7,093,000. RTW Investments LP grew its stake in shares of Tarsus Pharmaceuticals by 13.1% during the third quarter. RTW Investments LP now owns 2,880,701 shares of the company’s stock worth $51,190,000 after purchasing an additional 332,576 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 25.6% during the third quarter. Vanguard Group Inc. now owns 1,551,802 shares of the company’s stock worth $27,576,000 after purchasing an additional 316,128 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals during the third quarter worth $4,339,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS traded down $0.17 during mid-day trading on Friday, hitting $32.04. 373,901 shares of the company’s stock were exchanged, compared to its average volume of 717,980. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $12.57 and a fifty-two week high of $40.40. The firm has a market capitalization of $1.10 billion, a P/E ratio of -6.91 and a beta of 1.05. The business’s 50 day moving average is $34.02 and its two-hundred day moving average is $24.85. The company has a current ratio of 6.93, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $4.63 million. During the same quarter last year, the company posted ($0.49) EPS. On average, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -4.25 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the transaction, the general counsel now directly owns 40,951 shares of the company’s stock, valued at $1,253,100.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the completion of the transaction, the general counsel now directly owns 40,951 shares of the company’s stock, valued at $1,253,100.60. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Bobak R. Azamian sold 10,415 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $318,699.00. Following the completion of the transaction, the chief executive officer now directly owns 26,456 shares of the company’s stock, valued at $809,553.60. The disclosure for this sale can be found here. Insiders sold 24,496 shares of company stock valued at $749,578 over the last ninety days. Corporate insiders own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. HC Wainwright boosted their target price on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Barclays boosted their target price on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. The Goldman Sachs Group upped their price objective on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. Jefferies Financial Group upped their price objective on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, Oppenheimer restated an “outperform” rating and issued a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $48.38.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.